Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: New Appointments at CareDx, Sherlock Biosciences, DermTech, More

CareDx: Kashif Rathore, Ryan Phan, Sean Grant, and Danielle Scelfo

CareDx has appointed Kashif Rathore as senior VP of digital business, Ryan Phan as VP of lab operations, Sean Grant as VP of strategy and business development, and Danielle Scelfo as VP of market access and health policy.

Rathore joins CareDx from Cerner, where he held various senior leadership roles. In addition to his most recent role as VP of interoperability, Rathore served in the consulting and technology lines of Cerner's businesses.

Phan joins CareDx from Kaiser Permanente, where he served as managing director and head of regional molecular genetics and cytogenetics laboratories. He has led multiple strategic laboratory expansions and developed and implemented clinical testing programs.

Grant joins CareDx from Citigroup Global Capital Markets, where he served as a VP in the investment banking healthcare division. At Citigroup, Grant specialized in raising public and private capital and executed a broad range of transactions, including M&A, for many life sciences companies around the world.

Scelfo joins CareDx from Hologic, where she served as senior director of health policy and reimbursement. She has more than 25 years of health policy and strategic market access experience, including roles at Genomic Health and Adaptive Biotechnologies.


Sherlock Biosciences: Martin Madaus

Sherlock Biosciences has appointed Martin Madaus as chief operations officer. Madaus brings nearly 30 years of industry experience leading diagnostics companies across all stages of development through commercialization, and will lead Sherlock's business operations functions while supporting the company to scale to a fully functional commercial organization.

Madaus most recently served as interim CEO and executive chairman at Ultivue and Emulate Bio. He also served as chairman and CEO of Ortho Clinical Diagnostics from 2014 to 2019, leading the buyout through the Carlyle Group, where he continues to serve as operating executive. Prior to that, he served as president, chairman, and CEO of Millipore, which was acquired by Merck KGaA, and as CEO of Roche Diagnostics North America. Madaus also has extensive public and private company board experience and currently serves on the boards of Quanterix, Ultivue, Emulate Bio, and Candela Medical.


DermTech: Michael Howell

DermTech has appointed Michael Howell as CSO, a role in which he will coordinate research, new product development, and clinical validation efforts. Howell has over twenty years of academic and pharmaceutical industry experience. Prior to joining DermTech, he was the translational research lead for inflammation and autoimmunity at Incyte, driving the strategic expansion of Incyte’s pipeline in dermatology and other immunological disorders. Prior to that, he held various other roles within the pharmaceutical industry at Boehringer Ingelheim, Immune Tolerance Network, and MedImmune/AstraZeneca.

Howell also served as a faculty member in the Division of Allergy and Immunology at National Jewish Health. He earned a bachelor of science degree in biology from Messiah College and a doctorate in immunology from West Virginia University School of Medicine.


For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.

The Scan

Omicron's Emergence

The World Health Organization has called Omicron a SARS-CoV-2 "variant of concern," the Los Angeles Times writes.

Not as Much

Merck's pill to treat COVID-19 reduces the risk of hospitalization and death among COVID-19 patients by less than previously reported, the New York Times says.

Bats That Hang Together

Discover magazine writes that researchers have found a social microbiome among vampire bats.

PLOS Papers on CEWAS, Simian Varicella Virus Transcriptome, Dermatomyositis Markers

In PLOS this week: multi-omic approach to home in on genetic risk variants, transcriptomic analysis of the simian varicella virus, and more.